par prism | Oct 15, 2020 | News, Partenariats
The “Prism-Breast” project aims to understand the determinants of tumor response to anti-PD1 and beyond in patients who develop early stage triple negative breast cancer. Triple negative breast cancers represent 15% of breast cancers and most often have a...